-+ 0.00%
-+ 0.00%
-+ 0.00%

ELEVAR THERAPEUTICS ANNOUNCES FDA PDUFA DATE FOR RESUBMITTED NEW DRUG APPLICATION FOR RIVOCERANIB IN COMBINATION WITH CAMRELIZUMAB FOR USE AS A FIRST-LINE SYSTEMIC TREATMENT FOR UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA

Reuters·11/05/2026 16:13:57

Please log in to view news